LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 364

Search options

  1. Article ; Online: Small dense low-density lipoprotein particles: clinically relevant?

    Krauss, Ronald M

    Current opinion in lipidology

    2022  Volume 33, Issue 3, Page(s) 160–166

    Abstract: Purpose of review: Levels of small, dense low-density lipoprotein (LDL) (sdLDL) particles determined by several analytic procedures have been associated with risk of atherosclerotic cardiovascular disease (ASCVD). This review focuses on the clinical ... ...

    Abstract Purpose of review: Levels of small, dense low-density lipoprotein (LDL) (sdLDL) particles determined by several analytic procedures have been associated with risk of atherosclerotic cardiovascular disease (ASCVD). This review focuses on the clinical significance of sdLDL measurement.
    Recent findings: Results of multiple prospective studies have supported earlier evidence that higher levels of sdLDL are significantly associated with greater ASCVD risk, in many cases independent of other lipid and ASCVD risk factors as well as levels of larger LDL particles. A number of properties of sdLDL vs. larger LDL, including reduced LDL receptor affinity and prolonged plasma residence time as well as greater oxidative susceptibility and affinity for arterial proteoglycans, are consistent with their heightened atherogenic potential. Nevertheless, determination of the extent to which sdLDL can preferentially impact ASCVD risk compared with other apoprotein B-containing lipoproteins has been confounded by their metabolic interrelationships and statistical collinearity, as well as differences in analytic procedures and definitions of sdLDL.
    Summary: A growing body of data points to sdLDL concentration as a significant determinant of ASCVD risk. Although future studies should be aimed at determining the clinical benefit of reducing sdLDL levels, there is sufficient evidence to warrant consideration of sdLDL measurement in assessing and managing risk of cardiovascular disease.
    Video abstract: https://www.dropbox.com/s/lioohr2ead7yx2p/zoom_0.mp4?dl=0.
    MeSH term(s) Atherosclerosis ; Cardiovascular Diseases/complications ; Cholesterol, LDL ; Humans ; Lipoproteins ; Prospective Studies ; Risk Factors
    Chemical Substances Cholesterol, LDL ; Lipoproteins
    Language English
    Publishing date 2022-03-11
    Publishing country England
    Document type Journal Article ; Review ; Video-Audio Media
    ZDB-ID 1045394-5
    ISSN 1473-6535 ; 0957-9672
    ISSN (online) 1473-6535
    ISSN 0957-9672
    DOI 10.1097/MOL.0000000000000824
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Obesity and cardiovascular disease: beyond body weight and energy balance.

    Lechner, Katharina / Krauss, Ronald M

    European journal of preventive cardiology

    2022  Volume 29, Issue 17, Page(s) 2216–2217

    MeSH term(s) Humans ; Cardiovascular Diseases/diagnosis ; Cardiovascular Diseases/epidemiology ; Body Weight ; Obesity/complications ; Obesity/diagnosis ; Obesity/epidemiology ; Energy Metabolism ; Heart
    Language English
    Publishing date 2022-09-22
    Publishing country England
    Document type Editorial ; Comment
    ZDB-ID 2626011-6
    ISSN 2047-4881 ; 2047-4873
    ISSN (online) 2047-4881
    ISSN 2047-4873
    DOI 10.1093/eurjpc/zwac220
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Changes in soluble LDL receptor and lipoprotein fractions in response to diet in the DIETFITS weight loss study.

    Krauss, Ronald M / Fisher, Lois M / King, Sarah M / Gardner, Christopher D

    Journal of lipid research

    2024  Volume 65, Issue 3, Page(s) 100503

    Abstract: Circulating levels of the soluble ligand-binding ectodomain of the LDL receptor (sLDLR) that is proteolytically cleaved from the cell surface have been shown to correlate with plasma triglycerides, but the lipid and lipoprotein effects of longitudinal ... ...

    Abstract Circulating levels of the soluble ligand-binding ectodomain of the LDL receptor (sLDLR) that is proteolytically cleaved from the cell surface have been shown to correlate with plasma triglycerides, but the lipid and lipoprotein effects of longitudinal changes in sLDLR have not been examined. We sought to assess associations between changes in sLDLR and detailed lipoprotein measurements between baseline and 6 months in participants in the DIETFITS (Diet Intervention Examining The Factors Interacting with Treatment Success) weight loss trial who were randomly assigned to the low-fat (n = 225) or low-carbohydrate (n = 236) diet arms. sLDLR was assayed using a proteomic procedure, lipids and apoprotein (apo) B and apoAI were measured by standard assays, and lipoprotein particle subfractions were quantified by ion mobility methodology. Changes in sLDLR were significantly positively associated with changes in plasma cholesterol, triglycerides, apoB, large-sized and medium-sized VLDL, and small and very small LDL, and inversely with changes in large LDL and HDL. The lipoprotein subfraction associations with sLDLR were independent of age, sex, diet, and BMI, but all except for large LDL were reduced to insignificance when adjusted for triglyceride change. Principal component analysis identified three independent clusters of changes in lipoprotein subfractions that accounted for 78% of their total variance. Change in sLDLR was most strongly correlated with change in the principal component that was loaded positively with large VLDL and small and very small LDL and negatively with large LDL and HDL. In conclusion, sLDLR is a component of a cluster of lipids and lipoproteins that are characteristic of atherogenic dyslipidemia.
    MeSH term(s) Humans ; Proteomics ; Lipoproteins ; Triglycerides ; Receptors, LDL ; Diet ; Weight Loss ; Lipoproteins, LDL ; Lipoproteins, VLDL
    Chemical Substances Lipoproteins ; Triglycerides ; Receptors, LDL ; Lipoproteins, LDL ; Lipoproteins, VLDL
    Language English
    Publishing date 2024-01-19
    Publishing country United States
    Document type Randomized Controlled Trial ; Journal Article ; Research Support, Non-U.S. Gov't ; Research Support, N.I.H., Extramural
    ZDB-ID 80154-9
    ISSN 1539-7262 ; 0022-2275
    ISSN (online) 1539-7262
    ISSN 0022-2275
    DOI 10.1016/j.jlr.2024.100503
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Remnant lipoprotein particles and cardiovascular disease risk.

    Krauss, Ronald M / King, Sarah M

    Best practice & research. Clinical endocrinology & metabolism

    2022  Volume 37, Issue 3, Page(s) 101682

    Abstract: Intravascular catabolism of chylomicrons and very low-density lipoproteins (VLDLs) gives rise to a spectrum of partially lipolyzed remnant particles. Their plasma levels and properties are influenced by lipases, lipid transfer proteins, and content of ... ...

    Abstract Intravascular catabolism of chylomicrons and very low-density lipoproteins (VLDLs) gives rise to a spectrum of partially lipolyzed remnant particles. Their plasma levels and properties are influenced by lipases, lipid transfer proteins, and content of exchangeable lipoproteins. Particularly important among the latter are apoE, which mediates hepatic binding and uptake of remnants, and apoCIII, which can retard this process. In the course of their plasma transit, remnants can acquire pathologic properties that promote the development of atherosclerotic cardiovascular disease (ASCVD) including increased cholesterol content and transport of thrombogenic and inflammatory mediators. Levels of cholesterol-enriched remnant particles determined by various analytic techniques have been significantly linked to the incidence of ASCVD, most dramatically in dyslipidemic patients homozygous for the apoE2 genetic isoform. Further research is warranted for development of clinical assays that can better capture the pathologic impact of remnant lipoprotein subspecies, and for testing the impact on ASCVD of therapies that reduce their levels.
    MeSH term(s) Humans ; Triglycerides/metabolism ; Cardiovascular Diseases/epidemiology ; Cardiovascular Diseases/etiology ; Cholesterol/metabolism ; Chylomicrons/metabolism ; Atherosclerosis/genetics ; Atherosclerosis/metabolism
    Chemical Substances Triglycerides ; Cholesterol (97C5T2UQ7J) ; Chylomicrons
    Language English
    Publishing date 2022-06-08
    Publishing country Netherlands
    Document type Journal Article ; Review
    ZDB-ID 2052339-7
    ISSN 1878-1594 ; 1532-1908 ; 1521-690X
    ISSN (online) 1878-1594 ; 1532-1908
    ISSN 1521-690X
    DOI 10.1016/j.beem.2022.101682
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article: Concerns regarding NMR lipoprotein analyses performed on the Nightingale heath platform - Focus on LDL subclasses.

    Krauss, Ronald M / Remaley, Alan T / John Chapman, M

    Journal of clinical lipidology

    2022  Volume 16, Issue 3, Page(s) 250–252

    MeSH term(s) Humans ; Lipoproteins ; Lipoproteins, HDL ; Lipoproteins, LDL ; Magnetic Resonance Spectroscopy
    Chemical Substances Lipoproteins ; Lipoproteins, HDL ; Lipoproteins, LDL
    Language English
    Publishing date 2022-02-23
    Publishing country United States
    Document type Editorial ; Research Support, Non-U.S. Gov't
    ZDB-ID 2365061-8
    ISSN 1876-4789 ; 1933-2874
    ISSN (online) 1876-4789
    ISSN 1933-2874
    DOI 10.1016/j.jacl.2022.02.007
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article: TOMM40 and TOMM22 of the Translocase Outer Mitochondrial Membrane Complex rescue statin-impaired mitochondrial dynamics, morphology, and mitophagy in skeletal myotubes.

    Yang, Neil V / Rogers, Sean / Guerra, Rachel / Pagliarini, David J / Theusch, Elizabeth / Krauss, Ronald M

    bioRxiv : the preprint server for biology

    2023  

    Language English
    Publishing date 2023-06-26
    Publishing country United States
    Document type Preprint
    DOI 10.1101/2023.06.24.546411
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: VLDL receptor gene therapy for reducing atherogenic lipoproteins.

    Krauss, Ronald M / Lu, Jonathan T / Higgins, Joseph J / Clary, Cathryn M / Tabibiazar, Ray

    Molecular metabolism

    2023  Volume 69, Page(s) 101685

    Abstract: Over the past 40 years, there has been considerable research into the management and treatment of atherogenic lipid disorders. Although the majority of treatments and management strategies for cardiovascular disease (CVD) center around targeting low- ... ...

    Abstract Over the past 40 years, there has been considerable research into the management and treatment of atherogenic lipid disorders. Although the majority of treatments and management strategies for cardiovascular disease (CVD) center around targeting low-density lipoprotein cholesterol (LDL-C), there is mounting evidence for the residual CVD risk attributed to high triglyceride (TG) and lipoprotein(a) (Lp(a)) levels despite the presence of lowered LDL-C levels. Among the biological mechanisms for clearing TG-rich lipoproteins, the VLDL receptor (VLDLR) plays a key role in the trafficking and metabolism of lipoprotein particles in multiple tissues, but it is not ordinarily expressed in the liver. Since VLDLR is capable of binding and internalizing apoE-containing TG-rich lipoproteins as well as Lp(a), hepatic VLDLR expression has the potential for promoting clearance of these atherogenic particles from the circulation and managing the residual CVD risk not addressed by current lipid lowering therapies. This review provides an overview of VLDLR function and the potential for developing a genetic medicine based on liver-targeted VLDLR gene expression.
    MeSH term(s) Cholesterol, LDL ; Receptors, LDL/metabolism ; Genetic Therapy
    Chemical Substances VLDL receptor ; Cholesterol, LDL ; Receptors, LDL
    Language English
    Publishing date 2023-02-04
    Publishing country Germany
    Document type Journal Article ; Review ; Research Support, Non-U.S. Gov't
    ZDB-ID 2708735-9
    ISSN 2212-8778 ; 2212-8778
    ISSN (online) 2212-8778
    ISSN 2212-8778
    DOI 10.1016/j.molmet.2023.101685
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Ketogenic Diet Intervention on Metabolic and Psychiatric Health in Bipolar and Schizophrenia: A Pilot Trial.

    Sethi, Shebani / Wakeham, Diane / Ketter, Terence / Hooshmand, Farnaz / Bjornstad, Julia / Richards, Blair / Westman, Eric / Krauss, Ronald M / Saslow, Laura

    Psychiatry research

    2024  Volume 335, Page(s) 115866

    Abstract: The ketogenic diet (KD, also known as metabolic therapy) has been successful in the treatment of obesity, type 2 diabetes, and epilepsy. More recently, this treatment has shown promise in the treatment of psychiatric illness. We conducted a 4-month pilot ...

    Abstract The ketogenic diet (KD, also known as metabolic therapy) has been successful in the treatment of obesity, type 2 diabetes, and epilepsy. More recently, this treatment has shown promise in the treatment of psychiatric illness. We conducted a 4-month pilot study to investigate the effects of a KD on individuals with schizophrenia or bipolar disorder with existing metabolic abnormalities. Twenty-three participants were enrolled in a single-arm trial. Results showcased improvements in metabolic health, with no participants meeting metabolic syndrome criteria by study conclusion. Adherent individuals experienced significant reduction in weight (12 %), BMI (12 %), waist circumference (13 %), and visceral adipose tissue (36 %). Observed biomarker enhancements in this population include a 27 % decrease in HOMA-IR, and a 25 % drop in triglyceride levels. In psychiatric measurements, participants with schizophrenia showed a 32 % reduction in Brief Psychiatric Rating Scale scores. Overall Clinical Global Impression (CGI) severity improved by an average of 31 %, and the proportion of participants that started with elevated symptomatology improved at least 1-point on CGI (79 %). Psychiatric outcomes across the cohort encompassed increased life satisfaction (17 %) and enhanced sleep quality (19 %). This pilot trial underscores the potential advantages of adjunctive ketogenic dietary treatment in individuals grappling with serious mental illness.
    MeSH term(s) Humans ; Bipolar Disorder/epidemiology ; Diabetes Mellitus, Type 2 ; Diet, Ketogenic ; Pilot Projects ; Proof of Concept Study ; Schizophrenia/epidemiology
    Language English
    Publishing date 2024-03-20
    Publishing country Ireland
    Document type Clinical Trial ; Journal Article
    ZDB-ID 445361-x
    ISSN 1872-7123 ; 1872-7506 ; 0925-4927 ; 0165-1781
    ISSN (online) 1872-7123 ; 1872-7506
    ISSN 0925-4927 ; 0165-1781
    DOI 10.1016/j.psychres.2024.115866
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Book ; Conference proceedings: Genetic influences on lipoprotein response to dietary fat and cholesterol

    Krauss, Ronald M.

    proceedings of a symposium held in Anaheim, CA, April 26, 1994

    1995  

    Author's details guest scientific ed.: Ronald M. Krauss
    Keywords Lipoproteins / metabolism / congresses ; Lipoproteins / genetics / congresses ; Cholesterol, Dietary / administration & dosage / congresses ; Dietary Fats / administration & dosage / congresses
    Language English
    Publishing country United States
    Document type Book ; Conference proceedings
    Note In: The American journal of clinical nutrition. - ISSN 0002-9165. - 62 (1995),2, S. 457S - 492S
    HBZ-ID HT006708036
    Database Catalogue ZB MED Medicine, Health

    Kategorien

  10. Article ; Online: VLDL receptor gene therapy for reducing atherogenic lipoproteins

    Ronald M. Krauss / Jonathan T. Lu / Joseph J. Higgins / Cathryn M. Clary / Ray Tabibiazar

    Molecular Metabolism, Vol 69, Iss , Pp 101685- (2023)

    2023  

    Abstract: Over the past 40 years, there has been considerable research into the management and treatment of atherogenic lipid disorders. Although the majority of treatments and management strategies for cardiovascular disease (CVD) center around targeting low- ... ...

    Abstract Over the past 40 years, there has been considerable research into the management and treatment of atherogenic lipid disorders. Although the majority of treatments and management strategies for cardiovascular disease (CVD) center around targeting low-density lipoprotein cholesterol (LDL-C), there is mounting evidence for the residual CVD risk attributed to high triglyceride (TG) and lipoprotein(a) (Lp(a)) levels despite the presence of lowered LDL-C levels. Among the biological mechanisms for clearing TG-rich lipoproteins, the VLDL receptor (VLDLR) plays a key role in the trafficking and metabolism of lipoprotein particles in multiple tissues, but it is not ordinarily expressed in the liver. Since VLDLR is capable of binding and internalizing apoE-containing TG-rich lipoproteins as well as Lp(a), hepatic VLDLR expression has the potential for promoting clearance of these atherogenic particles from the circulation and managing the residual CVD risk not addressed by current lipid lowering therapies. This review provides an overview of VLDLR function and the potential for developing a genetic medicine based on liver-targeted VLDLR gene expression.
    Keywords Lipid disorders ; VLDL ; VLDL receptor ; Triglycerides ; lipoprotein(a) ; Gene therapy ; Internal medicine ; RC31-1245
    Subject code 616
    Language English
    Publishing date 2023-03-01T00:00:00Z
    Publisher Elsevier
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

To top